|EP101-C01||High-bind Plate||1 plate|
|EP101-C02||Human PD-L1||25 μg|
|EP101-C03||Anti-PD-1 Neutralizing Antibody||20 μg|
|EP101-C04||Human PD-1-Biotin||5 μg|
|EP101-C06||Coating Buffer||12 mL|
|EP101-C07||10xWashing Buffer||50 mL|
|EP101-C08||Blocking Buffer||50 mL|
|EP101-C09||Substrate Solution||12 mL|
|EP101-C10||Stop Solution||7 mL|
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Your experiment will include 4 simple steps:
a) Coat the plate with human PD-L1.
b) Add your molecule of interest to the tests.
c) Add human PD-1-Biotin to bind the coated human PD-L1.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit PD-1 : PD-L1 binding will be determined by comparing OD readings among different experimental groups.
BINDING OF BIOTINYLATED HUMAN PD-1 TO IMMOBILIZED HUMAN PD-L1 IN A FUNCTIONAL ELISA ASSAY.
Immobilized human PD-L1 protein at 2 μg/mL (100 μL/well) can bind human PD-1-Biotin with a linear range of 0.01-0.2 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting (QC tested).
INHIBITION OF PD-1-PD-L1 BINDING BY ANTI-PD-1 NEUTRALIZING ANTIBODY (CATALOG # EP101-C03) MEASURED USING THE PD-1 [BIOTINYLATED] : PD-L1 INHIBITOR SCREENING ELISA ASSAY PAIR (CATALOG # EP-101).
Anti-PD-1 neutralizing antibody was diluted from 10 μg/mL to 0.078 μg/ mL (69.628 nM to 0.544 nM) and loaded onto the plate coated by human PD-L1 in the presence of human PD-1-Biotin. Assay was performed according to the protocol in PD-1[Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Price(USD) : $600.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.